FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1489721537> ?p ?o ?g. }

• W1489721537 endingPage "239" @default.
• W1489721537 startingPage "236" @default.
• W1489721537 abstract "Fulvestrant is an estrogen receptor antagonist with no agonist effects. In the second-line treatment of advanced breast carcinoma, fulvestrant was shown previously to be as effective as the third-generation aromatase inhibitor, anastrozole, in terms of time to disease progression and objective response rates. The authors reported the overall survival results from these studies.A prospectively planned, combined, overall survival analysis was performed, including data from two Phase III trials that compared the efficacy and tolerability of fulvestrant (250 mg monthly; n = 428) with anastrozole (1 mg daily; n = 423) in the treatment of postmenopausal women with advanced breast carcinoma who had disease progression after receipt of previous endocrine treatment.At an extended median follow-up of 27.0 months (range, 0-66.9 months), 319 (74.5%) patients in the fulvestrant group and 322 (76.1%) patients in the anastrozole group had died. Prolonged survival was observed with both drugs, with 10-20% of patients still alive > 5 years after randomization. The median overall survival was similar between treatments, being 27.4 months and 27.7 months in fulvestrant and anastrozole-treated patients, respectively (hazards ratio, 0.98; 95% confidence interval, 0.84-1.15; P = 0.809). Fulvestrant continued to be well tolerated, and was associated with a significantly lower incidence of joint disorders compared with anastrozole (P = 0.0234).The current analysis showed that fulvestrant was similar to anastrozole with respect to overall survival in the second-line treatment of postmenopausal women with advanced breast carcinoma." @default.
• W1489721537 created "2016-06-24" @default.
• W1489721537 creator A5010188774 @default.
• W1489721537 creator A5015900909 @default.
• W1489721537 creator A5035522047 @default.
• W1489721537 creator A5037774999 @default.
• W1489721537 creator A5058219705 @default.
• W1489721537 creator A5058535647 @default.
• W1489721537 creator A5060188343 @default.
• W1489721537 creator A5068970824 @default.
• W1489721537 creator A5073889721 @default.
• W1489721537 date "2005-01-01" @default.
• W1489721537 modified "2023-09-25" @default.
• W1489721537 title "Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma" @default.
• W1489721537 cites W1453600927 @default.
• W1489721537 cites W1839333839 @default.
• W1489721537 cites W1934173384 @default.
• W1489721537 cites W1983621028 @default.
• W1489721537 cites W1995662976 @default.
• W1489721537 cites W200263122 @default.
• W1489721537 cites W2062073156 @default.
• W1489721537 cites W2132180344 @default.
• W1489721537 cites W2133667885 @default.
• W1489721537 cites W2139726760 @default.
• W1489721537 cites W2142944582 @default.
• W1489721537 cites W2202169216 @default.
• W1489721537 cites W2508460892 @default.
• W1489721537 cites W4300776185 @default.
• W1489721537 doi "https://doi.org/10.1002/cncr.21163" @default.
• W1489721537 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15937908" @default.
• W1489721537 hasPublicationYear "2005" @default.
• W1489721537 type Work @default.
• W1489721537 sameAs 1489721537 @default.
• W1489721537 citedByCount "149" @default.
• W1489721537 countsByYear W14897215372012 @default.
• W1489721537 countsByYear W14897215372013 @default.
• W1489721537 countsByYear W14897215372014 @default.
• W1489721537 countsByYear W14897215372015 @default.
• W1489721537 countsByYear W14897215372016 @default.
• W1489721537 countsByYear W14897215372017 @default.
• W1489721537 countsByYear W14897215372018 @default.
• W1489721537 countsByYear W14897215372019 @default.
• W1489721537 countsByYear W14897215372020 @default.
• W1489721537 countsByYear W14897215372021 @default.
• W1489721537 countsByYear W14897215372022 @default.
• W1489721537 countsByYear W14897215372023 @default.
• W1489721537 crossrefType "journal-article" @default.
• W1489721537 hasAuthorship W1489721537A5010188774 @default.
• W1489721537 hasAuthorship W1489721537A5015900909 @default.
• W1489721537 hasAuthorship W1489721537A5035522047 @default.
• W1489721537 hasAuthorship W1489721537A5037774999 @default.
• W1489721537 hasAuthorship W1489721537A5058219705 @default.
• W1489721537 hasAuthorship W1489721537A5058535647 @default.
• W1489721537 hasAuthorship W1489721537A5060188343 @default.
• W1489721537 hasAuthorship W1489721537A5068970824 @default.
• W1489721537 hasAuthorship W1489721537A5073889721 @default.
• W1489721537 hasBestOaLocation W14897215371 @default.
• W1489721537 hasConcept C121608353 @default.
• W1489721537 hasConcept C126322002 @default.
• W1489721537 hasConcept C143998085 @default.
• W1489721537 hasConcept C197934379 @default.
• W1489721537 hasConcept C207103383 @default.
• W1489721537 hasConcept C2776215463 @default.
• W1489721537 hasConcept C2777176818 @default.
• W1489721537 hasConcept C2778375690 @default.
• W1489721537 hasConcept C2778504769 @default.
• W1489721537 hasConcept C2780482068 @default.
• W1489721537 hasConcept C29456083 @default.
• W1489721537 hasConcept C44249647 @default.
• W1489721537 hasConcept C530470458 @default.
• W1489721537 hasConcept C71924100 @default.
• W1489721537 hasConceptScore W1489721537C121608353 @default.
• W1489721537 hasConceptScore W1489721537C126322002 @default.
• W1489721537 hasConceptScore W1489721537C143998085 @default.
• W1489721537 hasConceptScore W1489721537C197934379 @default.
• W1489721537 hasConceptScore W1489721537C207103383 @default.
• W1489721537 hasConceptScore W1489721537C2776215463 @default.
• W1489721537 hasConceptScore W1489721537C2777176818 @default.
• W1489721537 hasConceptScore W1489721537C2778375690 @default.
• W1489721537 hasConceptScore W1489721537C2778504769 @default.
• W1489721537 hasConceptScore W1489721537C2780482068 @default.
• W1489721537 hasConceptScore W1489721537C29456083 @default.
• W1489721537 hasConceptScore W1489721537C44249647 @default.
• W1489721537 hasConceptScore W1489721537C530470458 @default.
• W1489721537 hasConceptScore W1489721537C71924100 @default.
• W1489721537 hasIssue "2" @default.
• W1489721537 hasLocation W14897215371 @default.
• W1489721537 hasLocation W14897215372 @default.
• W1489721537 hasOpenAccess W1489721537 @default.
• W1489721537 hasPrimaryLocation W14897215371 @default.
• W1489721537 hasRelatedWork W1532577738 @default.
• W1489721537 hasRelatedWork W1760940766 @default.
• W1489721537 hasRelatedWork W1970376111 @default.
• W1489721537 hasRelatedWork W1998137765 @default.
• W1489721537 hasRelatedWork W2007182497 @default.
• W1489721537 hasRelatedWork W2015778822 @default.
• W1489721537 hasRelatedWork W2037739232 @default.
• W1489721537 hasRelatedWork W2056214045 @default.

• next